TuHURA Biosciences, Inc. (HURA)

TuHURA Biosciences, Inc. (HURA) Healthcare & Pipeline Overview

TuHURA Biosciences, Inc., a phase 3 immuno-oncology company, is dedicated to pioneering innovative technologies to combat resistance in cancer immunotherapy. With a focus on novel solutions, TuHURA operates in the biotechnology sector, aiming to improve treatment outcomes and address unmet needs in cancer care, while headquartered in Tampa, Florida.

What Is the Investment Thesis for HURA?

TuHURA Biosciences, Inc. presents a notable research candidate due to its focus on overcoming resistance to cancer immunotherapy, a significant challenge in the field. As a phase 3 registration-stage company, HURA is nearing potential commercialization of its lead product candidate. Successful completion of phase 3 trials and subsequent regulatory approval could drive substantial revenue growth. The company's market capitalization of $149.97M suggests significant upside potential if its therapies prove effective and gain market traction. However, the negative beta of -0.32 indicates that the stock price may move in the opposite direction of the market. Investors should carefully consider the risks associated with clinical trials and regulatory approval processes.

Based on FMP financials and quantitative analysis

HURA Key Highlights

• TuHURA Biosciences, Inc. is in phase 3 registration, indicating advanced stage of product development.
• The company focuses on immuno-oncology, a high-growth area within healthcare.
• TuHURA aims to overcome resistance to cancer immunotherapy, addressing a critical unmet need.
• The company is headquartered in Tampa, Florida, providing access to a growing biotechnology hub.
• TuHURA has a market capitalization of $149.97M.

Who Are HURA's Competitors?

HURA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HURA's Key Strengths?

• Focus on overcoming resistance to cancer immunotherapy.
• Phase 3 registration-stage company.
• Experienced management team.
• Proprietary technologies.

What Are HURA's Weaknesses?

• Small company with limited resources.
• Dependence on the success of its lead product candidate.
• Limited commercial infrastructure.
• Negative beta indicates potential volatility.

What Could Drive HURA Stock Higher?

• Completion of phase 3 clinical trials for lead product candidate.
• Potential regulatory approval from the FDA.
• Expansion of research and development pipeline.
• Strategic partnerships and collaborations.

What Are the Key Risks for HURA?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approval for its therapies.
• Unsuccessful clinical trials.
• Competition from larger biotechnology and pharmaceutical companies.
• Patent challenges.
• Negative beta indicates potential volatility.

What Are the Growth Opportunities for HURA?

• Expansion into New Therapeutic Areas: TuHURA can leverage its expertise in immuno-oncology to expand into new therapeutic areas beyond its current focus. By exploring new targets and mechanisms of action, the company can broaden its pipeline and address a wider range of cancers. The market for targeted cancer therapies is projected to grow significantly, offering substantial opportunities for TuHURA to diversify its product portfolio. Timeline: 3-5 years.
• Strategic Partnerships and Collaborations: TuHURA can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its therapies. Collaborations can provide access to new technologies, funding, and market expertise, enhancing TuHURA's competitive position. The pharmaceutical industry is increasingly relying on partnerships to drive innovation, creating a favorable environment for such collaborations. Timeline: Ongoing.
• Geographic Expansion: TuHURA can expand its geographic reach by entering new markets outside of the United States. International markets, particularly in Asia and Europe, offer significant growth opportunities for immuno-oncology therapies. By establishing a presence in these markets, TuHURA can tap into a larger patient population and increase its revenue potential. Timeline: 2-4 years.
• Acquisition of Complementary Technologies: TuHURA can acquire companies with complementary technologies to enhance its research and development capabilities. Acquiring companies with expertise in areas such as drug delivery or diagnostics can strengthen TuHURA's pipeline and improve its ability to develop innovative therapies. The biotechnology industry is characterized by frequent mergers and acquisitions, creating opportunities for TuHURA to expand its capabilities through strategic acquisitions. Timeline: 1-3 years.
• Development of Companion Diagnostics: TuHURA can develop companion diagnostics to identify patients who are most likely to respond to its therapies. Companion diagnostics can improve treatment outcomes and reduce healthcare costs by ensuring that patients receive the most appropriate therapy. The market for companion diagnostics is growing rapidly, driven by the increasing demand for personalized medicine. Timeline: 2-3 years.

What Opportunities Does HURA Have?

• Expansion into new therapeutic areas.
• Strategic partnerships and collaborations.
• Geographic expansion.
• Acquisition of complementary technologies.

What Threats Does HURA Face?

• Competition from larger biotechnology and pharmaceutical companies.
• Failure to obtain regulatory approval for its therapies.
• Unsuccessful clinical trials.
• Patent challenges.

What Are HURA's Competitive Advantages?

• Proprietary technologies that overcome resistance to cancer immunotherapy.
• Strong intellectual property protection for its therapies.
• Advanced stage of clinical development (phase 3 registration).
• Experienced management team with expertise in immuno-oncology.

What Does HURA Do?

TuHURA Biosciences, Inc., headquartered in Tampa, Florida, is a phase 3 registration-stage immuno-oncology company focused on developing innovative technologies to overcome resistance to cancer immunotherapy. The company is dedicated to advancing the field of cancer treatment by creating novel solutions that address the challenges of immunotherapy resistance. TuHURA's primary focus is on developing and commercializing therapies that can enhance the effectiveness of existing immunotherapies and provide new treatment options for patients who do not respond to current treatments. The company's research and development efforts are centered on identifying and targeting the mechanisms that cancer cells use to evade the immune system. By understanding these mechanisms, TuHURA aims to develop therapies that can restore the immune system's ability to recognize and destroy cancer cells. TuHURA is currently in phase 3 registration, indicating that its lead product candidate is in the final stages of clinical development and is nearing potential regulatory approval. The company's strategic location in Tampa, Florida, provides access to a vibrant biotechnology community and a skilled workforce, supporting its research and development activities. TuHURA's commitment to innovation and its focus on addressing a critical unmet need in cancer care position it as a key player in the immuno-oncology space.

What Products and Services Does HURA Offer?

• Develop novel technologies to overcome resistance to cancer immunotherapy.
• Conduct phase 3 clinical trials to evaluate the safety and efficacy of its therapies.
• Seek regulatory approval for its therapies from agencies such as the FDA.
• Commercialize its therapies to treat cancer patients.
• Engage in research and development to identify new targets and mechanisms of action.
• Collaborate with other biotechnology and pharmaceutical companies to advance its pipeline.

How Does HURA Make Money?

• Develop and commercialize immuno-oncology therapies.
• Generate revenue through the sale of its therapies.
• Partner with other companies to co-develop and co-market its therapies.
• License its technologies to other companies.

What Industry Does HURA Operate In?

The biotechnology industry is characterized by rapid innovation and intense competition, with companies racing to develop new therapies for unmet medical needs. Immuno-oncology, in particular, has emerged as a promising area, with significant advancements in recent years. TuHURA Biosciences, Inc. operates within this dynamic landscape, focusing on overcoming resistance to cancer immunotherapy. The global immuno-oncology market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of cancer and the growing demand for more effective treatments. TuHURA's focus on addressing immunotherapy resistance positions it to capture a share of this expanding market.

Who Are HURA's Key Customers?

• Cancer patients who are resistant to existing immunotherapies.
• Oncologists who treat cancer patients.
• Hospitals and cancer centers.
• Pharmaceutical companies that partner with TuHURA.

FY2026 estForward Outlook

Wall Street analysts project TuHURA Biosciences, Inc. revenue of about $10.5M for fiscal 2026, with EPS near $-0.56. The estimate reflects 3 contributing analysts.

F-Score 1/9Financial Health

TuHURA Biosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.98 places it in the safe zone, indicating low near-term bankruptcy risk.

Key Financial Metrics

Its free cash flow yield is -18.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.0%, the inverse of the P/E and a quick read on earnings relative to price.

TuHURA Biosciences, Inc. (HURA) Valuation Context

Valued at $149.97M, HURA is classified as a micro-cap stock. Relative to its peer group, HURA's quantitative score of 48/100 is below the peer average of 76/100.

Company Profile

TuHURA Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tampa, US. The company is led by CEO James A. Bianco. HURA has traded publicly since 2013.

HURA Financials

HURA Latest News

HURA Analyst Consensus

HURA MoonshotScore

Common Questions About HURA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources